Akeso, Inc.
康方生物科技（開曼）有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9926)

VOLUNTARY ANNOUNCEMENT

THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR THE EBDAROKIMAB INJECTION (IL-12/IL-23 MONOCLONAL ANTIBODY, AK101) INDEPENDENTLY-DEVELOPED BY AKESO

This announcement is made by Akeso, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the National Medical Products Administration ("**NMPA**") of China has accepted the New Drug Application ("**NDA**") for the Company's independently-developed ebdarokimab injection (research and development code: AK101), a wholly human IgG1 monoclonal antibody targeting IL-12/IL-23 for the treatment of moderate to severe plaque psoriasis. Ebdarokimab is the sixth in-house developed innovative drug which has received NDA approval or submitted NDA application.

A total of 5 clinical studies of ebdarokimab in patients with plaque psoriasis were conducted, of which 2 were pivotal Phase III clinical studies to evaluate the key efficacy data of ebdarokimab for 16 weeks and long-term 52 weeks in patients with moderate-to-severe plaque psoriasis.

The results show:

- Ebdarokimab demonstrates outstanding efficacy in patients with moderate-to-severe plaque psoriasis of both 16-week and 52-week treatment. Ebdarokimab is safe and well tolerated.

- Ebdarokimab can improve the quality of life of patients while improving skin condition.

The number of patients with psoriasis in China has exceeded 6 million, and the prevalence increases continuously. Psoriasis is a chronic and disabling disease which negatively impacts on patients' quality of life, which results in an overall heavy burden of disease for patients. In 2022, the market size of psoriasis treatment medications in China was approximately USD1.1 billion, and is expected to reach USD9.5 billion in 2030. As the first domestic new IL-12/IL-23 monoclonal antibody with outstanding efficacy and safety, ebdarokimab, is expected to provide more efficient, safe, convenient and economical treatment for patients in China.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: there is no assurance that ebdarokimab (AK101, IL-12/IL-23) will ultimately be successfully marketed and developed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Akeso, Inc.
Dr. XIA Yu
Chairwoman and executive director

Hong Kong, August 24, 2023

As of the date of this announcement, the Board of the Company comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Mr. XIA Yu (Ph.D.) as executive directors, Dr. ZHOU Yi and Mr. XIE Ronggang as non-executive directors, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.